Continuous hemodiafiltration in the treatment of reactive hemophagocytic syndrome refractory to medical therapy

Transfusion and Apheresis Science

Volumn 40, Issue 1, 2009, Pages 33-40

  Tateishi, Yoshihisa ^a   Oda, Shigeto ^a   Sadahiro, Tomohito ^a   Nakamura, Masataka ^a   Hirayama, You ^a   Abe, Ryuzo ^a   Hirasawa, Hiroyuki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Blood purification; Continuous hemodiafiltration (CHDF); Continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter (PMMA CHDF); Hemophagocytic syndrome (HPS); Hypercytokinemia

Indexed keywords

CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; ETOPOSIDE; FERRITIN; IMMUNOGLOBULIN; INTERLEUKIN 6; METHYLPREDNISOLONE; POLY(METHYL METHACRYLATE); PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FILTER; HEMOPHAGOCYTIC SYNDROME; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MALE; MULTIPLE ORGAN FAILURE; NEWBORN; PRESCHOOL CHILD; REMISSION;

ADOLESCENT; ADULT; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HEMODIAFILTRATION; HUMANS; INFANT, NEWBORN; INFLAMMATION MEDIATORS; INTENSIVE CARE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; POLYMETHYL METHACRYLATE; RETROSPECTIVE STUDIES;

EID: 59649092853     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.11.001     Document Type: Article

References (42)

1. Tsuda H. Hemophagocytic syndrome (HPS) in children and adults. Int J Hematol 65 (1997) 215-226
2. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol 66 (1997) 135-151
3. Fisman D.N. Hemophagocytic syndromes and infection. Emerg Infect Dis 6 (2000) 601-608
4. Larroche C., and Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 3 (2004) 69-75
5. Janka G.E. Hemophagocytic syndromes. Blood Rev 21 (2007) 245-253
6. Henter J.I., Horne A., Arico M., Egeler R.M., Filipovich A.H., Imashuku S., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 (2007) 124-131
7. Imashuku S. Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol 72 (2000) 1-11
8. Hirasawa H., Oda S., Shiga H., and Matsyda K. Endotoxin absorption or hemodiafiltration in the treatment of multiple organ failure. Curr Opin Crit Care 6 (2000) 482-486
9. Matsuda K., Hirasawa H., Oda S., Shiga H., and Nakanishi K. Current topics on cytokine removal technologies. Ther Apher 5 (2001) 306-314
10. Oda S., Hirasawa H., Shiga H., Nakanishi K., Matsuda K., and Nakamura M. Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 6 (2002) 193-198
11. Vincent J.L., de Mendonca A., Cantraine F., Moreno R., Takala J., Suter P.M., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 26 (1998) 1793-1800
12. Sadahiro T., Hirasawa H., Oda S., Shiga H., Nakanishi K., Kitamura N., et al. Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure. Crit Care Med 29 (2001) 1386-1392
13. Ohtake Y., Hirasawa H., Sugai T., Oda S., Shiga H., Matsuda K., et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 93 (1991) 215-217
14. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985) 818-829
15. Ishii E., Ohga S., Aoki T., Yamada S., Sako M., Tasaka H., et al. Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interleukin-1 and tumor necrosis factor. Acta Haematol 85 (1991) 93-99
16. Ohga S., Matsuzaki A., Nishizaki M., Nagashima T., Kai T., Suda M., et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol Oncol 15 (1993) 291-298
17. Watanabe M., Shimamoto Y., Yamaguchi M., Inada S., Miyazaki S., and Sato H. Viral-associated haemophagocytosis and elevated serum TNF-alpha with parvovirus-B19-related pancytopenia in patients with hereditary spherocytosis. Clin Lab Haematol 16 (1994) 179-182
18. Akashi K., Hayashi S., Gondo H., Mizuno S., Harada M., Tamura K., et al. Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 87 (1994) 243-250
19. Fujiwara F., Hibi S., and Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol 15 (1993) 92-98
20. Esumi N., Ikushima S., Todo S., and Imashuku S. Hyperferritinemia in malignant histiocytosis and virus-associated hemophagocytic syndrome. N Engl J Med 316 (1987) 346-347
21. Kaito K., Kobayashi M., Katayama T., Otsubo H., Ogasawara Y., Sekita T., et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 59 (1997) 247-253
22. Emmenegger U., Frey U., Reimers A., Fux C., Semela D., Cottagnoud P., et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 68 (2001) 4-10
23. Allen C.E., Yu X., Kozinetz C.A., and McClain K.L. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 50 (2008) 1227-1235
24. Oda S., Hirasawa H., Shiga H., Nakanishi K., Matsuda K., and Nakamua M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 29 (2005) 169-175
25. Nahum E., Ben-Ari J., Stain J., and Schonfeld T. Hemophagocytic lymphohistiocytic syndrome: unrecognized cause of multiple organ failure. Pediatr Crit Care Med 1 (2000) 51-54
26. Aukrust P., Froland S.S., Liabakk N.B., Muller F., Nordoy I., Haug C., et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84 (1994) 2136-2143
27. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 44 (2002) 259-272
28. Matsumoto Y., Naniwa D., Banno S., and Sugiura Y. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher 2 (1998) 300-304
29. Satomi A., Nagai S., Nagai T., Niikura K., Ideura T., Ogata H., et al. Effect of plasma exchange on refractory hemophagocytic syndrome complicated with myelodysplastic syndrome. Ther Apher 3 (1999) 317-319
30. Goto S., Aoike I., Shibasaki Y., Morita T., Miyazaki S., Shimizu T., et al. A successfully treated case of disseminated tuberculosis-associated hemophagocytic syndrome and multiple organ dysfunction syndrome. Am J Kidney Dis 38 (2001) E19
31. Kfoury Baz E.M., Mikati A.R., and Kanj N.A. Reactive hemophagocytic syndrome associated with thrombotic thrombocytopenic purpura during therapeutic plasma exchange. Ther Apher 6 (2002) 159-162
32. Sanada S., Ookawara S., Shindo T., Morino K., Ishikawa H., and Suzuki M. A case report of the effect of plasma exchange on reactive hemophagocytic syndrome associated with toxic shock syndrome. Ther Apher Dial 8 (2004) 503-506
33. Kitazawa Y., Saito F., Nomura S., Ishii K., and Kadota E. A case of hemophagocytic lymphohistiocytosis after the primary Epstein-Barr virus infection. Clin Appl Thromb Hemost 13 (2007) 323-328
34. Song K.S., and Sung H.J. Effect of plasma exchange on the circulating IL-6 levels in a patient with fatal hemophagocytic syndrome associated with bile ductopenia. Ther Apher Dial 10 (2006) 87-89
35. Henzan T., Nagafuji K., Tsukamoto H., Miyamoto T., Gondo H., Imashuku S., et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 81 (2006) 59-61
36. Nakada T.A., Oda S., Matsuda K., Sadahiro T., Nakamura M., Abe R., et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 14 (2008) 257-263
37. Hirayama Y., Hirasawa H., Oda S., Shiga H., Nakanishi K., Matsuda K., et al. The change in renal replacement therapy on acute renal failure in general intensive care unit in a university hospital and its clinical efficacy: a Japanese experience. Ther Apher 7 (2003) 475-482
38. Bagshaw O.N., Anaes F.R., and Hutchinson A. Continuous arteriovenous haemofiltration and respiratory function in multiple organ systems failure. Intens Care Med 18 (1992) 334-338
39. Heering P., Morgera S., Schmitz F.J., Schmitz G., Willers R., Schultheiss H.P., et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intens Care Med 23 (1997) 288-296
40. Nakanishi K., Hirasawa H., Sugai T., Oda S., Shiga H., Kitamura N., et al. Efficacy of continuous hemodiafiltration for patients with congestive heart failure. Blood Purif 20 (2002) 342-348
41. Henter J.I., Samuelsson-Horne A., Arico M., Egeler R.M., Elinder G., Filipovich A.H., et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100 (2002) 2367-2373
42. Favara B.E., Jaffe R., and Egeler R.M. Macrophage activation and hemophagocytic syndrome in langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol 5 (2002) 130-140